Our results indicated that XFPC capsules could reduce autophagy levels, maintain ciliary function, and improve the inflammatory status in vivo by interfering with the expression of CSF1, MAPK9, MAP3K7, and AKT3 in the MAPK pathway suggesting that TAK1-JNK/p38 pathway may be the target pathway of Xuanfei Pingchuan Fang in treating COPD. Here, AKT3 is linked to chronic obstructive pulmonary disease.